Clinique Victor Hugo — Clinical Trial Site

88 Registered trials

35 Currently recruiting

Organisation

Clinique Victor Hugo

Location

Le Mans, France

Identifier

ORG-100032493

Address

Centre De Cancerologie De La Sarthe, 66 Rue De Degre, 72000, France

Departments

-
#3350: Hématologie
125008
2315 Oncology Medical
409: Hematologie
Biologie médicale
Breast Oncology
Centre Jean Bernard (Atlas), Clinique Victor Hugo
FR30004 Plateforme de Recherche, Clinique Département Investigation, Oncologie-Hematologie
Generalist Medicine
Haematology
Hématologie
Hématologie clinique
Hematology
Medecine nucleaire
Medical Oncology
Medical Oncology Department
N/A
Onco-Haematology
Onco-hématologie
ONCO-RADIOTHERAPY
ONCOLOGIE
Oncologie Médicale
Oncologie Radiothérapie
Oncologie Thérapeutique
Oncologie-Radiothérapie
Oncology
Oncology - radiotherapy
Oncology – radiotherapy
Oncology and Radiotherapy
Oncology radiotherapy
Oncology-Radiotherapy
Oncoloy-Radiotherapy
Radiotherapy
Radiotherapy - oncology
Radiotherapy_ Oncology
Radiotherapy-oncology
Radiothezapy - Oncology
Service d'oncologie médicale
Service de radiothérapie

Clinical trials at this site (88)

Search interface

C2321003: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men with Metastatic Castration-Resistant… Recruiting

2024-511652-40-00 METASTATIC CASTRATION RESISTANT PROSTATE CANCER 5 2025-02-05
A phase 3 study to evaluate petosemtamab vs. investigator's choice in previously treated metastatic / recurrent head and neck cancer. Recruiting

2023-510322-32-00 patients with incurable, metastatic/recurrent head and 5 2025-01-27
A phase 3 study to evaluate petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of head and neck cancer Recruiting

2023-510323-30-00 First-line treatment of recurrent or metastatic PD-L1+ 5 2025-01-24
A phase III, randomised, open-label, Multicenter International Trial comparing ruxolitinib with either HydRoxycarbamIDe or interferon Alpha … Recruiting

2024-516109-21-00 Polycythaemia Vera (PV) 5 2024-12-09
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys… Recruiting

2023-508960-31-00 Metastatic HER2-positive breast cancer 5 2024-12-03
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting

2024-512279-10-00 Triple Negative Breast Cancer 5 2024-11-25
PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting

2024-515297-27-00 colon carcinoma 5 2024-08-14
STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C… Recruiting

2023-505871-63-00 ER+, HER2- metastatic breast cancer following endocrine 5 2024-04-08
Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib… Recruiting

2023-503708-10-00 Locally advanced or metastatic breast cancer 5 2024-02-20
Capsaicin 179 mg patch versus oral Duloxetine in patients with chemotherapy-induced peripheral neuropathy: a phase 3 randomized multicentric… Recruiting

2023-504618-31-00 Chemotherapy induced peripheral neuropathy (CIPN) 5 2023-10-20
Evaluation of an initial treatment with bevacizumab in combination with chemotherapy and then in combination with niraparib in maintenance i… Recruiting

2023-504166-37-00 Advanced ovarian, tubal or peritoneal cancer. 4 2022-02-01
RElapse in previously irradiated Prostate bed : a phase I/II study of stereotactic Ablative reIRradiation potentiated by Metformine (REPAIR … Recruiting

2022-502642-27-00 RElapse in previously irradiated Prostate bed 9 2020-11-26
A Phase III trial of acetylsalicylic acid and atorvastatin in patients with castrate-resistant prostate cancer (PEACE 4) Recruiting

2023-508072-11-00 Castration-resistant prostate cancer 5 2019-06-26
Hyperthermic Intraperitoneal Chemotherapy in the treatment of Ovarian Cancer relapse Recruiting

2024-517390-24-00 Ovarian epithelial cancer : intraperitoneal resectable 5 2011-04-26
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Progressive Metastatic Castration-… Ended

2024-513968-25-00 Metastatic castration-resistant prostate cancer (mCRPC) 5 2025-04-28
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women with Breast Cancer Who Are Having Hormone Therapy Ended

2024-510719-31-00 Moderate to Severe Vasomotor Symptoms (VMS) 5 2025-01-24
A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Rec… Ended

2023-505617-24-00 Recurrent Ovarian Cancer with High Folate Receptor-Alph 4 2024-11-05
Tuvusertib Combined with Niraparib or Lartesertib in Participants with Epithelial Ovarian Cancer (DDRiver EOC 302) Ended

2024-511202-23-00 Epithelial ovarian cancer that progressed on prior PARP 4 2024-10-31
A phase 3, randomized, double- blind, study of ianalumab (VAY736) versus placebo in addition to eltrombopag in primary immune thrombocytopen… Ended

2024-512890-28-00 Primary immune thrombocytopenia (ITP) 5 2023-03-20
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic … Ended

2023-509825-38-00 Metastatic Non–Small Cell Lung Cancer 5 2022-12-01
Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanc… Ended

2023-510097-14-00 Patients with MMR deficient relapse or advanced / metas 5 2022-04-15
A study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). Ended

2024-512148-50-00 Non-small cell lung cancer 5 2022-03-03
Multi-drug treatment for breast cancer patients with brain metastases Ended

2024-510703-11-00 HER2+ metastatic breast cancer with isolated brain prog 4 2021-12-13
A Phase 3 Trial of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treat… Ended

2023-507698-16-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2021-10-14